- Short report
- Open Access
HHV-6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis
© The Author(s). 2017
Received: 13 October 2016
Accepted: 15 December 2016
Published: 11 January 2017
Human herpesviruses have been hypothesized as environmental triggers in the development of autoimmune thyroid diseases (AITD), and in particular active human herpesvirus 6A (HHV-6A) infection was detected in thyrocytes of Hashimoto’s thyroiditis (HT) patients, who also show specific anti-viral immune responses. On the other hand, AITD patients display modulation of specific miRNAs in thyroid tissue and blood. We wanted to ascertain whether HHV-6A infection might be correlated to the miRNA dysregulation observed in AITD.
Human thyroid and T-cell lines were infected in vitro with HHV-6A,-6B or −7, and analysed for miRNAs expression, either by microarray or by specific RT-PCR assays detecting miRNAs associated with AITD in vivo.
HHV-6A infection, but not -6B or −7 infections, induced a decrease in miR-155_2 expression and an increase in miR-1238 expression in thyrocytes, as well as an increase in the expression levels of several autoimmunity-associated miRNAs in T lymphocytes, including miR-16_1, miR34a, miR-130a, miR-143_1, miR-202, miR-301b, miR-302c, miR-449b, miR-451_1, and miR-1238_2.
HHV-6A infection modulates miRNAs expression in the cell types involved in the development of AITD. Notably, our in vitro findings correlate with what observed in AITD patients, further supporting the association between HHV-6A infection and AITD development. Moreover, these effects are 6A-specific, emphasizing the differences between the two HHV-6 virus species, and suggesting diverse virus mechanisms of action and therapeutic approaches.
Autoimmune thyroid diseases (AITD) are very common thyroid disorders, showing increased prevalence in recent years . In addition to genetic background, several viruses, including herpesviruses, have been suggested as possible environmental causes, but conclusive data are still lacking. In particular, we and others reported a high prevalence of active human herpesvirus 6A (HHV-6A) infection in thyrocytes of Hashimoto’s thyroiditis (HT) patients [2, 3], who also display specific cellular and humoral anti-viral responses, increased NK killing of infected thyroid cells , and increased CD3-CD56brightCD16−NK cells, whose activation significantly correlates with plasma levels of anti-thyroid peroxidase (TPO) and anti-thyroglobulin (Tg) autoantibodies .
HHV-6 is a ubiquitous virus including two distinct viral species, HHV-6A and HHV-6B, displaying different cellular tropism and receptors usage [5–8]. Although originally considered lymphotropic, the in vivo tropism of both viruses is considerably broader, including macrophages, endothelial cells, salivary glands, and brain . HHV-6B is associated with childhood exanthema subitum, whereas HHV-6A is mostly adult-associated, and has been correlated to several chronic autoimmune inflammatory diseases, including AITD [5, 9].
On the other hand, some microRNAs (miRNA) have been found dysregulated in AITD patients and implicated in the disease development. In particular, miR-155_2 has been found decreased and miR-200a1 increased in HT thyroid tissue compared with healthy controls , whereas miR-16, miR-22, miR-375 and miR-451 were found increased in serum of HT and Grave’s Disease (GD) patients, compared with controls .
Some miRNAs function has been associated with the control of innate and adaptive immune responses , but further work is needed to understand the role of miRNAs and their potential as disease markers and/or therapeutic targets in autoimmune thyroiditis. Furthermore, no data are available on the potential ability of HHV-6 to induce miRNAs modulation in cells involved in the disease development (i.e. thyrocytes and lymphocytes).
Based on these observations, the present study was addressed to ascertain whether HHV-6A infection might induce modulation of those miRNAs associated in vivo with AITD, and particularly with HT.
In vitro virus infection
The human thyroid Nthy-ori3-1 and Jurkat T cell lines were used for in vitro infection experiments. The cells were propagated and seeded at optimal density , then infected with HHV-6A, −6B or −7 cell-free virus inocula, at a m.o.i. of 10 genome equivalents per cell, as previously detailed . Control cells were infected with the correspondent UV-inactivated viruses, and virus infection was monitored by analyzing virus presence and transcription in infected cells, respectively by real time quantitative PCR (qPCR) and qPCR after retrotranscription (RT-qPCR), amplifying the U42 gene of all viruses, as previously described .
The mature miRNA fraction was extracted from infected or control cells by the miRNeasy mini kit (Qiagen, Hilden, Germany), and retro-transcribed as indicated by the manufacturer (miScript RT kit; Qiagen, Hilden, Germany). miRNA fraction was then analysed by a microarray detecting a panel of 84 microRNAs specifically associated to inflammation and autoimmunity (Qiagen, Hilden, Germany), and by specific real time quantitative PCR (qPCR) assays for the following miRNAs: miR-16-1_1, miR-16_2, miR-22, miR-34a, miR-143_1, miR-146a_1, miR-155_1, miR-155_2, miR-181a_1, miR-181a_2, miR-200a_1, miR-200a_2, miR-375, miR-451miR-1238_2. Two assays detecting constitutively expressed cellular miRNAs (miR-RTC and miR-SNORD11) were also used as controls.
Statistical analysis of collected data was performed by Student’s t test.
Herpesvirus infection in human thyroid and T-cell lines
miRNA expression in infected thyroid and T-cell lines
miRNA expression in infected cells was analysed at 0, 7, 24, 48, 72 h post infection (h.p.i.) and 7 days post infection (d.p.i.). Briefly, the mature miRNA fraction was extracted from infected and control cells, retro-transcribed and analysed by two different qPCR methods. At 48 h.p.i., extracted miRNAs were analysed by a qPCR microarray detecting a panel of 84 microRNAs specifically associated to inflammation and autoimmunity; at all times post infection miRNA fraction was instead analysed by specific qPCR assays detecting the following miRNAs: miR-16-1_1, miR-16_2, miR-22, miR-34a, miR-143_1, miR-146a_1, miR-155_1, miR-155_2, miR-181a_1, miR-181a_2, miR-200a_1, miR-200a_2, miR-375, miR-451miR-1238_2; miR-RTC and miR-SNORD11 were used as internal controls.
In parallel, the individual analysis of AITD-related miRNAs in Jurkat T cells evidenced, in HHV-6A infected cells only, statistically significant increases in the expression of miR-16_1 (13-fold peak at 7 h.p.i.), miR-143_1 (28-fold peak at 48 h.p.i.), miR-451_1 (36-fold peak at 48 h.p.i.) and miR-1238_2 (~104-fold increase at 48 and 72 h.p.i.) (p < 0.0001 and p < 0.001) (Fig. 3b). On the other hand, similarly to what observed in thyroid cells, no significant alteration in miRNA expression were observed in HHV-6B or HHV-7 infected T cells, except for a slight increase in miR-155_2 levels in HHV-7 infected cells at 7 h.p.i.
Our data show for the first time that in vitro HHV-6A infection of human cells of thyroid and T lymphoid origin (namely Nthy-ori3-1 and Jurkat cell lines) induces modulation of miRNAs considered markers of AITD in vivo. Notably, the virus-induced alterations correlate with what observed in vivo, as AITD patients, particularly those affected by HT, have decreased miR-155_2 in thyroid tissue , and increased miR-16 in serum .
Due to their emerging role as important regulators of immune function , the virus-induced dysregulation of these miRNAs might have important consequences in the development of autoimmunity. In particular, miR-155 is a pleiotropic modulator of innate and adaptive immunity [15–17], and might promote autoimmune inflammation . Beside its role as tumor-suppressor , miR-16 was recently shown to affect NK function by repressing IFNγ expression , and to promote M1 pro-inflammatory type macrophage polarization, affecting T cell activation . No data are instead available on miR-1238 potential functions in immunity, as it was so far recognized only as a tumor-suppressor factor . However, it was identified as a marker of AITD , together with miR-143_1, and the strong increase observed in both thyroid and lymphoid HHV-6A infected cells suggest a potential role of miR-1238 in the modulation of immune response, and deserves further studies.
Notably, significant alterations were detected only in HHV-6A infected cells, and not in HHV-6B or HHV-7 infected cells, further strengthening the notion that 6A and 6B species induce diverse effects inside infected cells, and are associated to diverse diseases. Since all used HHV show superimposable structural features and ability to enter and replicate in infected cells, the observed differences might be attributable to factors induced or expressed differently by these viruses inside infected cells. These factors may include both viral and virus-induced cell compounds, which will be interesting to analyze in future studies.
Overall, our current findings add evidences supporting the association between HHV-6A infection and AITD onset, and suggest a potential role of the induced miRNA in the development ofHHV-6A associated diseases. Further studies are however needed to verify these effects in primary human cells and to assess the functional role of virus-induced miRNAs in the development of the virus-induced autoimmunity.
We thank Iva Pivanti and Erica Gentilin for their excellent technical assistance.
This work was partially supported by Funds for Basic Research of the University of Ferrara.
Availability of data and materials
The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.
EC conceived and designed the experiments; EC, MD, IS performed the experiments; MCZ, RR, EU analysed and discussed the data; EC and DDL wrote the paper. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42:252–65.View ArticlePubMedGoogle Scholar
- Thomas D, Liakos V, Michou V, Kapranos N, Kaltsas G, Tsilivakos V, Tsatsoulis A. Detection of herpes virus DNA in post-operative thyroid tissue specimens of patients with autoimmune thyroid disease. Exp Clin Endocrinol Diabetes. 2008;116:35–9.View ArticlePubMedGoogle Scholar
- Caselli E, Zatelli MC, Rizzo R, Benedetti S, Martorelli D, Trasforini G, Cassai E, Degli Uberti EC, Di Luca D, Dolcetti R. Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto’s thyroiditis. PLoS Pathog. 2012;8:e1002951.View ArticlePubMedPubMed CentralGoogle Scholar
- Rizzo R, Zatelli MC, Rotola A, Cassai E, Degli Uberti E, Di Luca D, Caselli E: Increase in Peripheral CD3-CD56brightCD16- Natural Killer Cells in Hashimoto's Thyroiditis Associated with HHV-6 Infection. Adv Exp Med Biol. 2015;897:113–20.Google Scholar
- Caselli E, Di Luca D. Molecular biology and clinical associations of Roseoloviruses human herpesvirus 6 and human herpesvirus 7. New Microbiol. 2007;30:173–87.PubMedGoogle Scholar
- Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, Flamand L, Frenkel N, Gallo R, Gompels UA, et al. Classification of HHV-6A and HHV-6B as distinct viruses. Arch Virol. 2014;159:863–70.View ArticlePubMedGoogle Scholar
- Tang H, Wang J, Mahmoud NF, Mori Y. Detailed study of the interaction between human herpesvirus 6B glycoprotein complex and its cellular receptor, human CD134. J Virol. 2014;88:10875–82.View ArticlePubMedPubMed CentralGoogle Scholar
- Jasirwan C, Furusawa Y, Tang H, Maeki T, Mori Y. Human herpesvirus-6A gQ1 and gQ2 are critical for human CD46 usage. Microbiol Immunol. 2014;58:22–30.View ArticlePubMedGoogle Scholar
- Broccolo F, Fusetti L, Ceccherini-Nelli L. Possible role of human herpesvirus 6 as a trigger of autoimmune disease. Scientific World Journal. 2013;2013:867389.View ArticlePubMedPubMed CentralGoogle Scholar
- Bernecker C, Lenz L, Ostapczuk MS, Schinner S, Willenberg H, Ehlers M, Vordenbaumen S, Feldkamp J, Schott M. MicroRNAs miR-146a1, miR-155_2, and miR-200a1 are regulated in autoimmune thyroid diseases. Thyroid. 2012;22:1294–5.View ArticlePubMedGoogle Scholar
- Yamada H, Itoh M, Hiratsuka I, Hashimoto S. Circulating microRNAs in autoimmune thyroid diseases. Clin Endocrinol (Oxf). 2014;81:276–81.View ArticleGoogle Scholar
- Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell. 2009;136:26–36.View ArticlePubMedGoogle Scholar
- Caselli E, Bracci A, Galvan M, Boni M, Rotola A, Bergamini C, Cermelli C, Dal Monte P, Gompels UA, Cassai E, Di Luca D. Human herpesvirus 6 (HHV-6) U94/REP protein inhibits betaherpesvirus replication. Virology. 2006;346:402–14.View ArticlePubMedGoogle Scholar
- Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol. 2008;9:839–45.View ArticlePubMedGoogle Scholar
- Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316:608–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn 2nd GW, et al. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol. 2013;191:5904–13.View ArticlePubMedGoogle Scholar
- Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, Katsikis PD. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nat Immunol. 2013;14:593–602.View ArticlePubMedPubMed CentralGoogle Scholar
- O’Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, Baltimore D. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010;33:607–19.View ArticlePubMedPubMed CentralGoogle Scholar
- Pekarsky Y, Croce CM. Role of miR-15/16 in CLL. Cell Death Differ. 2015;22:6–11.View ArticlePubMedGoogle Scholar
- Leong JW, Sullivan RP, Fehniger TA. microRNA management of NK-cell developmental and functional programs. Eur J Immunol. 2014;44:2862–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Jia X, Li X, Shen Y, Miao J, Liu H, Li G, Wang Z. MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation. J Cell Mol Med. 2016;20:1898–907.Google Scholar
- Shi X, Zhan L, Xiao C, Lei Z, Yang H, Wang L, Zhao J, Zhang HT. miR-1238 inhibits cell proliferation by targeting LHX2 in non-small cell lung cancer. Oncotarget. 2015;6:19043–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway. Cell Cycle. 2008;7:2570–83.View ArticlePubMedGoogle Scholar